Search Results

IBEX Technologies Inc. is pleased to announce that at an annual and special meeting held , IBEX shareholders approved the previously-announced proposed amalgamation of IBEX and 15720273 Canada Inc., a newly-incorporated wholly-owned subsidiary of BBI Solutions OEM Limited, whereby BBI will acquire all of the issued and outstanding shares of IBEX at a price of $1.45 per share in cash.

IBEX Technologies Inc. announces that it has completed the sale of the company by amalgamating with 15720273 Canada Inc., a newly-incorporated wholly-owned subsidiary of BBI Solutions OEM Limited.

IBEX Technologies Inc. (“ IBEX ” or the “ Company ”) (TSX Venture: IBT) is pleased to announce that it has entered into a binding acquisition agreement dated February 9, 2024 (the “ Acquisition Agreement ”) and related agreements with 15720273 Canada Inc. (the “ Purchaser ”), a newly-incorporated, wholly-owned subsidiary of BBI Solutions OEM Limited (“ BBI ”), whereby BBI will acquire all of the issued and outstanding shares of IBEX at a price of $1.

IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the second quarter and the six months ended January 31, 2024.

IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the three months ended October 31, 2023.

IBEX Technologies Inc. announced that the TSX Venture Exchange has conditionally approved the renewal of IBEX’s normal course issuer bid.

IBEX Technologies Inc. announces that it has filed an addendum to its management proxy circular dated February 23, 2024 for the annual and special meeting of shareholders to be held in Montreal, Québec on April 3, 2024.

Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced excellent results across multiple clinical studies conducted with the University of Pittsburgh Medical Center (UPMC), Brigham and Women’s Hospital, Champalimaud Foundation and Ohio State University (OSU).